US-based pharmaceutical company Johnson & Johnson (NYSE: JNJ) on Friday announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor.

The study evaluated adults and adolescents 12 years of age and older with body surface area as low as 1% and at least moderate plaque psoriasis (PsO) affecting high-impact skin sites.

Data presented at the 2025 Society for Investigative Dermatology (SID) Annual Meeting showed that 57% of patients treated with once daily icotrokinra achieved the study's primary endpoint with an Investigator's Global Assessment (IGA)b score of 0/1 (clear or almost clear skin) and a greater than or equal to 2-grade improvement from baseline at Week 16 compared to 6% of patients receiving placebo (P